ACADIA Pharmaceuticals (Nasdaq: ACAD) updated its Phase III program for pimavanserin. This drug is being collaborated with Bioval Lobratories ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE